H-SPAN Summit D.C. 2026 | FDA Strategies for Longevity Biotech

Moderator: Eric Morgen Panelists: David M. Fox, Lowell Zeta, Robert Kalesnik-Orszulak Aging is not a recognized indication, which leaves every longevity company to find a path through a framework built for disease. This panel brings together regulatory counsel and former agency insiders to walk through what actually works: how to select an indication and endpoint the FDA will accept, which existing pathways and designations are available, how to structure early conversations with reviewers, and where companies most often lose time.